Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Granulomatosis with Polyangiitis and Microscopic Polyangiitis Treatment Study
The purpose of this study is to investigate the safety and efficacy of two different dose regimens as add-on to standard of care in subjects with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). A total of 36 patients will take part in this study at approximately 22 centers in the United States of America. At Rush, we expect to enroll approximately 2 participants.
In order to participate you must meet the following criteria:
- Are male or female, and at least 18 years of age or older.
- Have a diagnosis of GPA or MPA.
You will be excluded from the study if any of the following criteria apply to you:
- Have any other multisystem autoimmune disease.
This is a partial list of inclusion and exclusion criteria.